Citi downgraded Schrodinger (SDGR) to Neutral from Buy with a price target of $20, down from $35. The firm cites the recent developments in the company’s internally developed drug pipeline as well as continued headwinds facing the biotech and pharma industries, the analyst tells investors in a research note. Citi adds that its positive stance was largely based on the three shots on goal the company had in its early stage Phase 1 assets to highlight how its drug development platform could discover novel targets that biopharma partners would be interested in, but to date, Schrodinger’s recent updates have fallen short, raising concerns on the potential of the company’s proprietary drug portfolio efforts.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SDGR:
- Schrodinger’s Hold Rating: Challenges in Drug Pipeline and Software Growth Amid Macroeconomic Headwinds
- Schrodinger discontinues SGR-2921 clinical development program
- Schrodinger initiated with an Overweight at Barclays
- Schrodinger’s Strong Financial Performance and Promising Pipeline Developments Justify Buy Rating
- Schrodinger’s Strategic Growth and Financial Stability: Buy Rating Affirmed